E-drug: International Society for Pharmacoepidemiology
-------------------------------------------------------
Dear Fellow E-Druggers:
This is a call to those of you who are also members of the
International Society for Pharmacoepidemiology (ISPE).
I have been asked to edit the reborn newsletter for ISPE, to be called
Scribe.
As you are aware, essential drugs are a small part of the world of
most ISPE members. Our membership profile is dominated by regulators,
industry medical affairs personnel, and academics concerned with drug
safety and utilization. Not by intent, but by demographics, almost all of
the professional focus of ISPE is on the Europe-North America-Japan
axis. I would like to assist the elements within the Society that have a
different global perspective.
If there are issues that arise on E-DRUG list, or other points that you
think you might wish to address in a 300-500 essay aimed at the ISPE
membership, I would be really grateful to hear about it. The topic
should be of current interest, and the essay should be informational
rather than polemical. (This is not to say that you can't express an
opinion. There should be a preponderance of fact, to allow the reader
to form an opinion as well.)
Thank you in advance,
Alec
Alexander M. Walker
Department of Epidemiology
Harvard School of Public Health
Boston MA 02115
tel +1 617 432 4565
fax +1 617 566 7805
e-mail: amwalker@episun1.harvard.edu
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.